# Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL

> **NCT05472558** · PHASE1 · RECRUITING · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 48 (estimated)

## Conditions studied

- B-cell Non Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** anti-CD19 CAR-NK

## Key facts

- **NCT ID:** NCT05472558
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-26
- **Primary completion:** 2025-12
- **Final completion:** 2026-12
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05472558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05472558, "Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05472558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*